Lantern Pharma is a uniquely positioned life science company pushing innovations in pharmaceutical biotechnology and drug-companion diagnostic co-development through Artificial Intelligence, Machine Learning, and Genomics.
Download Company Overview – August 20th, 2020
Featured Lantern Pharma Coverage
Artificial Intelligence – How The Race To Create A True Thinking Machine Will Reshape Business
– Fortune Magazine, February 2020
Oncology drug development today is a perfect environment for A.I.
Oncology drug development is time consuming, costly and high risk, with rates of a successful outcome (drug approval) being very low. This is a perfect problem area for Lantern Pharma’s approach to pharmaceutical biotechnology involving machine learning and Artificial Intelligence.
*Wong, C. H., Siah, K. W., & Lo, A. W. (2019). Estimation of clinical trial success rates and related parameters. Biostatistics (Oxford, England), 20(2), 273–286. doi:10.1093/biostatistics/kxx069
Lantern Pharma has a targeted, personalized approach to oncology drug development RADR®
Lantern Pharma is a life science company leading the charge in advancing and accelerating the development of precision oncology therapeutics using A.I., genomics and machine learning to analyze biomarker signatures to develop personalized drug therapies.
- Data Driven – Our RADR® Precision Medicine platform analyzes genetic bio- marker data using advanced machine learning algorithms to stratify trial patients.
Research Led – The technology enables more efficient novel drug positioning, existing drug repositioning, and the rescue and repurposing of shelved therapeutic assets.
Results Oriented – Lantern is focused on personalizing cancer therapies for patients and potentially improving the outcome for the patient.
RADR® is being continually improved by Lantern Pharma for the development of our drug portfolio and to pinpoint patient groups that can be best treated by our therapies and the therapies of our partners.
RADR® Platform Architecture
Lantern Pharma’s pharmaceutical biotechnology solution is through the development of a process that accurately stratifies patient populations into responders and non-responders for a wide variety of oncology therapies to de-risk clinical trials, develop companion diagnostics and increase the potential for successful FDA approval with reduced costs.
Bringing breakthrough approaches that can potentially change the cost curve and risk involved in cancer therapy development requires an immense network of talented collaborators and partners. At Lantern Pharma we are constantly looking to involve our life science company with like minded companies, organizations and people.
Let’s start a conversation about the future of cancer drug development.
We are a biotech pharma at the intersection of Artificial Intelligence, genomics, and oncology drug development.